AdaptHealth Earnings Call Signals Growth Amid Headwinds
Adapthealth ((AHCO)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AdaptHealth’s latest earnings call struck an overall optimistic tone, as management highlighted solid operational execution, record patient volumes, and strong cash generation that enabled further debt reduction and credit upgrades. While investors must navigate near‑term headwinds from segment weakness, one‑time charges, and upfront costs tied to a major new capitated contract, the company’s upgraded 2026 outlook underscored confidence in its long‑term growth and margin trajectory.
Revenue Beat and Steady Organic Growth
AdaptHealth reported full‑year 2025 net revenue of $3.245 billion and fourth‑quarter revenue of $846.3 million, both above the midpoint of prior guidance. On an organic basis, revenue grew 1.7% for the full year and in Q4, signaling underlying demand resilience even as reported revenue was pressured by asset sales.
Patient Volumes Hit Records Across Core Franchises
The company posted record patient census in key categories, underscoring its scale in home‑based care. Sleep health reached 1.73 million patients, up 4% year over year, while new starts climbed about 6% to roughly 130,600, and respiratory and wellness segments also logged record census levels.
Sleep and Respiratory New Starts Drive Growth
Respiratory health saw new highs in both oxygen and ventilator patients, with oxygen census around 335,000 and vent volumes also setting records. New starts grew about 4% in oxygen and 5% in vents, while Wellness at Home posted 6% and 5% growth in wheelchair and bed starts, respectively, reinforcing AdaptHealth’s expanding footprint in chronic care support.
Adjusted EBITDA and Margins Remain Solid
Full‑year adjusted EBITDA reached $616.7 million with a 19.0% margin, and Q4 adjusted EBITDA was $163.1 million at a 19.3% margin. Management noted that excluding a $14.5 million legal settlement and roughly $10 million of accelerated capitated onboarding costs, EBITDA tracked in line with prior guidance, suggesting core profitability remains intact.
Robust Free Cash Flow and Cash Generation
Free cash flow for 2025 came in at $219.4 million, significantly above the high end of guidance and a key support for de‑leveraging. In Q4 alone, cash flow from operations reached $183.2 million and free cash flow was $79.3 million, giving the company flexibility to invest in growth and absorb temporary cost pressures.
Debt Reduction and Rating Upgrades Strengthen Balance Sheet
AdaptHealth continued to chip away at its leverage, reducing debt by $25 million in Q4 and $250 million year‑to‑date, bringing net debt to $1.694 billion and net leverage to 2.75x. Lower interest expense, down about $21 million year over year, and recent credit rating upgrades from both S&P and Moody’s reinforce a healthier capital structure.
Major Capitated Contract Win Supports Long‑Term Growth
Management spotlighted the closing of what they called the largest capitated contract in the industry, a key strategic milestone. The initial December go‑live across three Mid‑Atlantic states covering roughly 50,000 members was executed ahead of plan, with a 98% contact center answer rate, and the fully scaled agreement is expected to ultimately reach more than 10 million patients across 30 locations.
Operational and Technology Gains Boost Efficiency
The company’s standardized operating model has sharply cut referral‑to‑setup times, with sleep setups reduced to nine days from 23 a year earlier and respiratory setups improving by three days. Clinical adherence remains about 10 percentage points above the industry’s top quartile, while AI pilots, PAP self‑scheduling, and the MyAPP platform, now over 327,000 users, are lowering processing times and patient friction.
Guidance Highlights Growth and Margin Upside into 2026
For 2026, AdaptHealth guided to net revenue of $3.44–$3.51 billion, implying 6–8% growth, and adjusted EBITDA of $680–$730 million, with the midpoint suggesting a roughly 20.3% margin and about a one‑point improvement versus 2025. Management expects 7.5–9.5% organic growth, with 5–6% driven by the new capitated agreement, and forecast free cash flow of $175–$225 million alongside a quarter‑by‑quarter ramp that should reach low‑double‑digit growth by Q4.
Reported Revenue Slightly Down Amid Dispositions
Despite beating guidance, reported net revenue dipped modestly year over year as the company streamlined its portfolio. Full‑year revenue declined 0.5% and Q4 revenue fell 1.2% on a reported basis, with dispositions shaving $92.4 million from annual revenue, highlighting the gap between reported and organic performance.
Diabetes Health Weakness and Goodwill Impairment
The Diabetes Health segment remained a soft spot, with Q4 revenue of $158.5 million down 7.4% year over year as continuous glucose monitor new starts lagged and payer mix shifts reduced reimbursement per patient. Reflecting a more cautious outlook, the company booked a $128 million non‑cash goodwill impairment tied to this business, and management signaled a flat near‑term view pending sales and operational improvements.
Wellness at Home Revenue Hit by Asset Sales
Wellness at Home posted a 16.1% year‑over‑year revenue decline in Q4, driven primarily by the sale of noncore assets during 2025 rather than underlying demand erosion. While new starts remain healthy, investors should note the segment’s smaller reported base following these portfolio actions, which are part of a broader refocus on higher‑value growth areas.
One‑Time Legal Settlement and Onboarding Costs Weigh on Q4
Quarterly results reflected several exceptional items, including a $14.5 million legal settlement tied to a previously disclosed class action matter. The company also incurred about $10 million of accelerated costs to bring its new capitated arrangement live ahead of schedule, which temporarily pressured working capital and leverage but support future revenue and margin expansion.
Leverage and Working Capital Face Short‑Term Pressure
Net leverage ticked up slightly to 2.75x from 2.68x at the end of Q3, with unrestricted cash at $106.1 million. Working capital fell to $16.5 million, which management attributed to the legal settlement and increased infrastructure spending, signaling a near‑term balance sheet pinch as investments ramp ahead of associated revenue.
Capitated Ramp to Drive Near‑Term Margin and Cash Drag
The company warned that upfront spending tied to the capitated contract will weigh on early 2026 results, with Q1 free cash flow expected between negative $20 million and negative $40 million and an adjusted EBITDA margin around 16%. Capital expenditures stepped up to $103.9 million, or 12.3% of revenue, in Q4, and leadership suggested that elevated CapEx levels are broadly sustainable as they build out long‑term infrastructure.
Higher Run‑Rate Spending and Revolver Usage
To support equipment needs for the capitated deployment, AdaptHealth drew $100 million on its revolving credit facility, including highlighted equipment acquisition costs of $47.6 million. These borrowings will temporarily increase leverage until free cash flow ramps over 2026, but management views the spending as critical to capture the contract’s embedded growth and profit potential.
Segment‑Specific Risks and Uncertain Diabetes Recovery
Management flagged segment‑level risks, particularly in Diabetes Health where demand for continuous glucose monitors and new starts remain subdued and the recovery timeline is uncertain. They are investing in sales and operational upgrades but are keeping expectations broadly flat in this segment for now, underscoring the importance of other franchises and the capitated contract to overall growth.
In closing, AdaptHealth’s earnings call painted a picture of a company leaning into scale, technology, and value‑based care to drive future growth, even as it absorbs near‑term financial friction. For investors, the story now hinges on successful execution of the massive capitated contract, stabilization in Diabetes, and delivery on 2026 guidance that points to higher revenue, stronger margins, and improving free cash flow despite a deliberately investment‑heavy start to the year.
